Abstract Cushing syndrome (CS) in children is rare. Delayed diagnosis and treatment of CS may be associated with increased morbidity and, unfortunately, mortality. We performed a retrospective review of all patients with CS under
Introduction
Few studies have reported mortality among children with Cushing syndrome (CS) [13, 14, 16, 29] . CS is a rare disease in children and adolescents, and this has contributed to both the lack of data and the fact that children with CS still occasionally die: in young patients timely diagnosis is challenging and may be missed due to the nonspecific signs and symptoms that can mislead pediatricians and even endocrinologists [28] . Mortality rates vary depending on the type of tumor, age, sex, years of hypercortisolism, and comorbidities that stem from it ( Table 2 ). The incidence of CS in children is less than two to three cases per million per year [19, 30] ; in addition, the average length of time for recorded symptoms prior to diagnosis of the condition exceeds 2 years [11, 31] . Although it has been suggested repeatedly that children with CS should receive treatment in a specialized center, it is still the case that a number of these patients are cared for in medical centers with no experience in the disease or even community hospitals [2, 31] .
In the present investigation, we report all the deaths that occurred among patients under the age of 18 years that were referred to the National Institutes of Health (NIH) in the last 15 years; the review of these cases that were identified retrospectively has important lessons to teach us for the management of children with CS.
Clinical protocol and methods
The charts of 160 children seen at or referred to the NIH with the diagnosis of CS from the year 1998 to 2013 were reviewed. All studies were conducted under clinical protocols 97CH0076, 00CH0160, and 95CH0059, all approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board. Informed consent from the patients' parents (and assent from older children) was obtained for all patients who were seen at the NIH. Diagnosis of CS was confirmed, as previously described [2, 31] .
Case records of deceased patients
Patient 1 was a 9.5-year-old female who initially presented to her pediatrician with weight gain and decreasing growth velocity during the previous 2 years. Physical examination revealed central obesity, facial plethora, and hepatosplenomegaly. Her first pediatric endocrinologist diagnosed her with congenital deficiency of growth hormone (GH) but the patient's height remained unchanged even after GH replacement treatment for 1 year. Another endocrinologist noted adrenocorticotropic hormone (ACTH)-independent hypercortisolism but because of an unremarkable adrenal computerized tomography (CT) she was referred to the NIH. Hypercortisolism was confirmed, due to an adrenal source (Table 1) . Pituitary magnetic resonance imaging (MRI) was unremarkable (Table 1) . She underwent bilateral adrenalectomy and the pathology was consistent with bilateral, isolated micronodular adrenocortical disease (iMAD). She had the 171delTfs41X inactivating PDE11A mutation (case CAR36.03) [12] . Postoperatively, she developed a pancreatic fistula, which was drained. The patient was treated with systemic antibiotics and discharged in stable condition after 3 weeks at the NIH. After a week, she was admitted to a regional hospital with intractable vomiting and fever. She expired a few days later due to complications of gastroenteritis which led to necrotizing pancreatitis extensive fat necrosis and peritonitis with perisplenic abscess formation. Autopsy report also noted acute kidney tubular necrosis as well as pulmonary thromboemboli with pulmonary congestion.
Patient 2 was a 13-year-old male who initially presented to his pediatrician with weight gain and decrease in growth velocity during the preceding 2 years. Other symptoms included increased appetite, facial fullness, depression, fatigue, headaches, and increased pigmentation of the back of his neck, knuckles, and knees. He was referred to a pediatric endocrinologist who diagnosed him with hypertension (150/ 110 mmHg) and hypercortisolism (Table 1 ). An adrenal ultrasound and pituitary MRI were unremarkable. He was started on antihypertensive therapy and was referred to the NIH. CS was confirmed along with an elevated plasma ACTH (Table 1) ; an ovine cortisol releasing hormone test (oCRH test) and an 8 mg dexamethasone suppression test (8 mg DST) were consistent with an ectopic source of ACTH (Table 1) . His pituitary MRI was unremarkable and an adrenal CT showed enlarged adrenals. A chest CT showed a thymic mass encasing numerous vessels and extending to nodes into neck and axillae with no evidence of distant metastasis. Surgery revealed a thymic carcinoid and significant tumor infiltration into cervical, peritracheal, and paraesophageal lymph nodes [24] . Clinical screening and genetic testing for multiple endocrine neoplasia (MEN1) were negative. Due to continuing hypercortisolism, severe hypertension, hypokalemia, and hypercoagulability, he was transferred from the NIH to a chronic care facility where he died a few months later due to complications of his primary disease (i.e., airway obstruction). He passed away 3 years after the appearance of the first signs of CS. His case was included in our last series of patients with ectopic ACTH CS [24] .
Patient 3 was a 15.5-year-old female who initially presented to her pediatrician with complaints of increased weight gain during the last 4 years and significant changes in her facial features, presence of dorsocervical fat, and abdominal striae for 1 year. Other symptoms included increased appetite, hirsutism, headache, fatigue, polyuria, and difficulty in breathing. She was then referred to a tertiary medical center where the laboratory findings proved (Table 1) . She was suspected of having CS since she had high serum ACTH and she did not suppress her serum cortisol levels after a 1 mg DST (Table 1) . Pituitary MRI was unremarkable which prompted referral to the NIH. CS was confirmed, and the results of the 8 mg DST and the oCRH test were consistent with pituitary disease (Table 1 ). The patient was scheduled for transsphenoidal surgery (TSS), sent home, and due to come back for the procedure. The patient died 3 weeks prior to TSS at a regional hospital due to sepsis, although the origin of the infection remains unclear. She passed away 4 years after the appearance of the first signs of CS. Patient 4 was a 7.5-year-old female who initially presented to her pediatrician with increasing weight and decrease in growth velocity during the last 2.5 years. Other symptoms included facial plethora and flushing, obesity, dorsocervical fat pad, increased appetite, polyuria, headache, diplopia, depression, insomnia, and adult body odor. She was then referred to a pediatric endocrinologist, for further evaluation. Her laboratory findings showed hypercortisolism (Table 1 ), but after the 1 mg DST, serum cortisol levels were suppressed ( Table 1 ). The adrenal CT and the pituitary MRI were unremarkable. Her endocrinologist suggested cyclical CS due to high 24 h-UFC and referred her to the NIH. However, she died from complications of bronchopneumonia before admission to the NIH-CRC. The cause of CS was never identified and she passed away 3 years after the appearance of the first signs of CS.
Results
We retrospectively reviewed 160 pediatric patients with CS, referred to the NIH between 1998 and 2013 (Fig. 1) . Female to male predominance (86 females, 74 males) was similar to the adult population (Fig. 1) [19] . Of these children, 122 children had CD (76.25 %), 31 (19.37 %) had adrenal tumors, 6 (3.75 %) had ectopic production of ACTH, and one had CS from an unknown etiology (0.625 %). We identified four children (2.5 %) [(three females, one male), aged 7.5-15.5 years (mean age 11.2 years) with length of disease 2-4 years], whose death was attributed to the complications of CS. One of these four children was diagnosed with a pituitary adenoma, another with adrenal hyperplasia (iMAD), one with ectopic production of ACTH, and one had CS from an unknown etiology. Thus, in this study, mortality rates in the four main diagnostic categories of CS in children were 0.81 % (1:122) for pituitary adenoma, 3.22 % (1:31) for adrenal tumors, and 16.7 % (1:6) for ectopic ACTH-producing tumors.
There was nothing unusual about these patients in terms of the severity of their disease when they were first detected of having CS or at their presentation at the NIH-CRC after comparison to all other 156 patients. One patient even had cyclical, periodic CS which is typically mild. These children were referred to a specialized center, and the diagnosis and treatment were made according to pediatric-specific protocols [2, 19, 28, 31] . They all shared increasing weight gain accompanied and a slowing growth velocity, as we have reported before for children with CS [2, 31] . Other symptoms varied and included facial plethora and flushing, dorsocervical fat pads, striae, polyuria, hypertension, headache, vision disturbances, depression, and insomnia in other pediatric patients that have been reported [30] . Their cortisol levels and responses to tests (Table 1) were like any other patient with CS that we have seen in these last 15 years. The cause of death was related to sepsis in three of the four cases, whereas in one case it was due to the primary tumor.
Discussion
Few reports of pediatric mortality due to CS exist (Table 2 ) [13, 14, 16, 29] . Our study found a small but not negligible mortality rate among a large series of children with CS: 2.5 %. A number of studies on mortality in CS in adults are available [1, 4, 6, 7, 9, 17, 18, 22, 25, 26, 30, 33, 35] . The exact cause of death is not clearly stated in most cases, and data are not always standardized (size of the cohort, follow-up period, and definition of remission of the disease) [25] . The epidemiology of CS, the morbidity, and the mortality of CS in children and in adults are quite different [1, 25, 31] . Moreover, the mortality rate in CS might be attributed either to the main disease/tumor or to comorbidities that are caused by sustained hypercortisolism. In agreement with the previous studies, the mortality in our patients was mainly attributed either to infection/sepsis due to sustained hypercortisolism or to residual disease/progression of disease [7, 13, 25, 35] . The mortality rate according to type of disease/tumor in children is almost the same with adults ( Fig. 1) [9, 18] . Mortality is lower for CD, it is quite higher for adrenal tumors, and it is dramatically higher for ectopic ACTH-producing tumors (Table 2) .
Since these children were not different from any others in our cohort, what led to death in these four cases and what lessons can we derive from them? If one sets aside the child with the thymic carcinoid who died of complications of his primary tumor, the other three died of an infection that led to sepsis: in two, the cause was identified as gastroenteritis (one) and pneumonia (one); in the third, the primary infection is unknown. Although detailed immune workup is not available for any of the four children, we have to assume that sepsis developed in three of the four due to immunosuppression as a result of CS.
The immune-endocrine interactions are complex [20] . Hypercortisolemia from an endogenous or an exogenous source induces immune suppression and predisposes to opportunistic infections affecting mainly the cell-mediated immunity [27] . Some patients with CS may present with mucocutaneous fungal infections, postoperative wound infections, opportunistic bacterial infections (e.g., Pneumocystis carinii), or reactivation of latent tuberculosis [8] and other diseases. The duration and the degree of hypercortisolism correlate positively with the induced immune deficiency and the frequency and the severity of infection in all types of CS [8, 15, 20, 27, 32, 34] .
One could speculate on the basis of these data that any child with CS, even in the absence of any other predisposing factors or comorbidities, has a certain risk of sudden death, primarily due to uncontrolled complications of a primary infection. Hypercortisolism may mask the signs and symptoms of infection due to its potent anti-inflammatory actions explaining the high risk of sepsis in CS [8, 6, 35] . The assessment of immunodeficiency by means of the complete blood count or by the measurements of body temperature is not reliable in patients with CS. Moreover, these indices do not always correlate with the levels of cortisol, UFC, or urinary17-OH-steroids. Some clinicians suggest to start antibiotic prophylaxis in patients with severe hypercortisolism [27] . These are important to consider given that, due to its nonspecific initial signs and symptoms, in our experience, CS is diagnosed by referring endocrinologists at least 2 years from when pictures and growth chart data date the beginning of the disease [11, 31] .
The present data suggest that recognition of early signs and symptoms of CS is extraordinarily important; once the disease is diagnosed early treatment is essential. And finally, even after curative surgery, patients should be followed carefully as the risk of sepsis remains for some time [6] . Detailed investigation of the immune system recovery in patients with CS is lacking at this time, but one should have a low threshold for treating infections aggressively the first few months after cure of CS. Finally, referral to an experienced medical center for the treatment of CS and its complications has been mentioned before as an essential factor in providing state-of-theart care to these patients [10] .
